The present study aims to report the surgical outcome and long-term survival of conversion surgery and clarify its role in advanced gastric cancer.
Patients and Methods
A total of 95 primary advanced gastric adenocarcinoma patients who underwent systemic chemotherapy and conversion surgery were reviewed retrospectively. The survival of conversion surgery was analyzed by Cox regression and the Kaplan–Meier method. Surgical outcomes were analyzed according to the Clavien–Dindo classification.
The median survival time (MST) of the 95 patients was 26.8 months, and the postoperative MST was 19.3 months. The MSTs of the patients in categories 1, 2, 3, and 4 were 28.8, 25.5, 43.6, and 11.3 months, respectively. The MSTs of the patients who underwent R0 resection (47 cases) and R1/2 resection (48 cases) were 49.3 months and 21.9 months, respectively. The MST of patients treated with total gastrectomy was shorter (21.9 months) than that of patients who underwent proximal (55.0 months) or distal (46.3 months) gastrectomy. Patients who received more than 6 cycles of induction chemotherapy had a longer MST than patients who received 3–5 cycles or 1–2 cycles (MST: 55.0 months versus 21.1 months versus 21.7 months). The incident postoperative complications and postoperative mortality rates were 10.5% and 1.1%, respectively.
Advanced gastric cancer patients may obtain a survival benefit from conversion surgery, except category 4. Performing a sufficient number of cycles of induction chemotherapy (usually ≥ 6 cycles) is recommended. Surgical oncologists should perform R0 resection and avoid total gastrectomy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: Cancer J Clin. 2019; 69: 7–34. https://doi.org/10.3322/caac.21551
Wang W, Sun Z, Deng JY et al. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun. (Lond) 2018; 38: 23. https://doi.org/10.1186/s40880-018-0293-0
Gao K, Wu J. National trend of gastric cancer mortality in China (2003–2015): a population-based study. Cancer Commun. (Lond) 2019; 39: 24. https://doi.org/10.1186/s40880-019-0372-x
Shitara K, Özgüroğlu M, Bang Y-J et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392: 123–133. https://doi.org/10.1016/s0140-6736(18)31257-1
Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet 2016; 388: 2654–2664. https://doi.org/10.1016/s0140-6736(16)30354-3
Fujitani K, Yang H-K, Mizusawa J et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016; 17: 309–318. https://doi.org/10.1016/s1470-2045(15)00553-7
Wilke H, Muro K, Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1224–1235. https://doi.org/10.1016/s1470-2045(14)70420-6
Morgagni P, Solaini L, Framarini M et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018; 53: 360–365. https://doi.org/10.1016/j.ijsu.2018.04.016
Kanda T, Yajima K, Kosugi S, Ishikawa T, Ajioka Y, Hatakeyama K. Gastrectomy as a secondary surgery for stage IV gastric cancer patients who underwent S-1-based chemotherapy: a multi-institute retrospective study. Gastric Cancer 2012; 15: 235–244. https://doi.org/10.1007/s10120-011-0100-y
Nie R, Yuan S, Li Y et al. Risk-stratification model to select conversion surgery for advanced gastric cancer patients. Chin J Cancer Res. 2019; 31: 178–187. https://doi.org/10.21147/j.issn.1000-9604.2019.01.13
Fukuchi M, Ishiguro T, Ogata K et al. Prognostic role of conversion surgery for unresectable gastric cancer. Ann Surg Oncol. 2015; 22: 3618–3624. https://doi.org/10.1245/s10434-015-4422-6
Beom SH, Choi YY, Baek SE et al. Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. BMC Cancer 2018; 18: 1116. https://doi.org/10.1186/s12885-018-4998-x
Fukuchi M, Mochiki E, Ishiguro T et al. Efficacy of conversion surgery following S-1 plus cisplatin or oxaliplatin chemotherapy for unresectable gastric cancer. Anticancer Res. 2017; 37: 1343–1347. https://doi.org/10.21873/anticanres.11453
Yasufuku I, Nunobe S, Ida S et al. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer 2019. https://doi.org/10.1007/s10120-019-00994-0
Einama T, Abe H, Shichi S et al. Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer. Mol Clin Oncol. 2017; 6: 163–166. https://doi.org/10.3892/mco.2017.1128
Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 2017; 20: 1-19. https://doi.org/10.1007/s10120-016-0622-4
Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 2016; 19: 329–338. https://doi.org/10.1007/s10120-015-0575-z
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004; 240: 205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
Robert L. Camp MD-FaDLR. X-Tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004 10: 7252–7259
Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9: 215–221. https://doi.org/10.1016/s1470-2045(08)70035-4
Shah MA, Janjigian YY, Stoller R et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. J Clin Oncol. 2015; 33: 3874–3879. https://doi.org/10.1200/jco.2015.60.7465
Ahn DH, Grothey A. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncol. 2017; 18: 1427–1428. https://doi.org/10.1016/s1470-2045(17)30714-3
Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31–39. https://doi.org/10.1016/s0140-6736(13)61719-5
Catenacci DVT, Tebbutt NC, Davidenko I et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1467–1482. https://doi.org/10.1016/s1470-2045(17)30566-1
Ilfet Songun HP, Elma Meershoek-Klein Kranenbarg, Mitsuru Sasako, Cornelis J H van de Velde. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010; 11: 439–449. https://doi.org/10.1016/s14702045(10)70070-x
Yu J, Huang C, Sun Y et al. Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial. JAMA 2019; 321: 1983–1992. https://doi.org/10.1001/jama.2019.5359
Wook Kim M, Hyung-Ho Kim, Sang-Uk Han et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage i gastric cancer. Ann Surg. 2016; 263: 28–35. https://doi.org/10.1097/sla.0000000000001346
Ishigami H, Fujiwara Y, Fukushima R et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018; 36: 1922–1929. https://doi.org/10.1200/jco.2018.77.8613
The authors declare that they have no conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Yun Wang, Ying-Bo Chen are co-senior authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Chen, G., Yuan, S., Nie, R. et al. Surgical Outcome and Long-Term Survival of Conversion Surgery for Advanced Gastric Cancer. Ann Surg Oncol 27, 4250–4260 (2020). https://doi.org/10.1245/s10434-020-08559-7